GSK says key trial data shows its RSV vaccine is 'truly exceptional'
3 minute readPublished: Thursday, October 13, 2022 at 5:20 am
/cloudfront-us-east-2.images.arcpublishing.com/reuters/WRDM6CSMBVPEZFFWEOTHGVMOPI.jpg)
Late-stage data unveiled on Thursday showed GSK's respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly-watched late-stage study involving older adults.